Ozuriftamab vedotin is under clinical development by BioAtla and currently in Phase II for Recurrent Head And Neck Cancer Squamous Cell Carcinoma. According to GlobalData, Phase II drugs for Recurrent Head And Neck Cancer Squamous Cell Carcinoma have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ozuriftamab vedotin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ozuriftamab vedotin overview
BA-3021 is under development for the treatment of solid tumors include unresectable or metastatic, non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), melanoma, metastatic melanoma, pancreatic cancer, colorectal cancer, rectal carcinoid tumor, head and neck cancer, soft tissue sarcoma (STS), ovarian cancer, fallopian tube cancer, peritoneal cancer, recurrent or metastatic squamous cell carcinoma of the head and neck, oropharynx, oral cavity, hypopharynx, and larynx cancer. The drug candidate acts by targeting the cells expressing tyrosine-protein kinase transmembrane receptor (ROR2). It is developed based on conditionally active biologics (CAB) platform. It is administered through intravenous route.
BioAtla is a clinical-stage biopharmaceutical company that focused on on developing antibody-based therapeutics for the treatment of solid tumor cancer. The company product candidate includes BA3011, BA3021 and BA3071, BA3182, BA3142, BA3311, BA336 and BA3151. BioAtla lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugates (ADC) that targets AXL, which is protein kinase receptor. Its BA3021 is developing a CAB antibody drug conjugate directed against receptor tyrosine kinase such as orphan receptor 2 (ROR2), BA3071 is therapeutic for multiple solid tumor indications, including renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer and cervical cancer. The company offers laboratories in the US and China. BioAtla is headquartered in San Diego, California, the US.
For a complete picture of Ozuriftamab vedotin’s drug-specific PTSR and LoA scores, buy the report here.